The pharmaceutical company, Cassava Sciences (NASDAQ: SAVA) was up in pre-market trading on Friday after the company’s Director, Richard Barry, bought 18,477 shares at an average price of $16.67 per share. The transactions are valued at $307,928 and will raise Barry’s stake in the company.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Meanwhile, another director, Sanford Robertson, also purchased 30,000 shares of the company worth $523,500 at an average price of $17.45.
Overall, corporate insiders are positive about the company and have bought $832,400 worth of SAVA stock over the past three months
